Omega-3s & fish oil

Omega-3s are the strange case of this section: the mechanism is the most convincing of any food here, the human dataset is the largest, and the tier is still preclinical — because two decades of trials have failed to convert the lab story into a benefit for osteoarthritic joints.

The mechanism is real

In cartilage explants and chondrocytes, n-3 fatty acids incorporated into cell membranes dose-dependently reduce aggrecanase activity and switch off expression of IL-1α, TNF-α, and COX-2 — the core catabolic machinery of cartilage breakdown. The effect is specific to n-3s; n-6 and saturated fats don't do it. Omega-3s also compete with arachidonic acid, the substrate for pro-inflammatory eicosanoids, and in humans, higher arachidonic acid levels track with knee synovitis.

The trials are null

The cleanest test is recent: a 2024 JAMA trial randomized 262 adults with knee osteoarthritis to 2 g/day of krill oil or placebo for 24 weeks — and deliberately selected patients with effusion-synovitis on MRI, the inflammatory phenotype most expected to respond. Pain improved identically in both groups; the between-group difference was a third of a point on a 100-point scale, with a confidence interval straddling zero. An adequately powered null in the best-case population.

The next-largest trial compared high-dose fish oil (4.5 g/day omega-3) against low-dose (0.45 g/day) for two years in 202 knee-OA patients. High dose was no better — the low-dose arm actually improved more on pain and function, and MRI cartilage volume loss did not differ. With no placebo arm, no efficacy conclusion is possible in either direction, and the low-dose-wins pattern smells like regression to the mean. A meta-analysis of 42 marine-oil trials rounds out the picture: a small overall pain effect, driven almost entirely by rheumatoid arthritis; in the five osteoarthritis trials, the effect was non-significant. RA is an autoimmune inflammatory disease — its positive signal does not transfer to OA cartilage.

The cohort signal

The one genuinely encouraging human cartilage datum is observational. In 472 adults from the MOST cohort, higher plasma omega-3 and DHA levels were associated with less patellofemoral cartilage loss — though not tibiofemoral — while n-6 arachidonic acid was associated with synovitis. It's the strongest cartilage-specific human signal for any nutrient in this section, and it carries every limitation of a cross-sectional cohort: fish-eaters differ from non-fish-eaters in ways no model fully adjusts for, and a single-compartment finding could be chance. That signal has never been tested in a randomized design with a placebo — arguably the most important missing trial in this entry.

Where that leaves you

Given the nulls, no fish-oil dose can honestly be recommended for cartilage. The defensible framing is food, not capsules: fatty fish inside a Mediterranean-style pattern, which has its own (modest) evidence covered in the anti-inflammatory diet entry. Worth noting, too, that marine-oil trials frequently run on industry-supplied product, and the meta-analysis rated the overall evidence quality as low.

Safety is not the obstacle. Adverse events matched placebo in the krill trial (51 versus 54 percent). The known considerations are mild GI effects, fishy burps, dose-dependent effects on bleeding time at high intakes, and caution alongside anticoagulants. If a long, placebo-controlled trial with MRI cartilage endpoints ever tests the cohort signal properly, this entry gets rewritten; until then, omega-3s are a good mechanism still waiting for a positive human result.